MedAware vs VigiLanz (2026)
The layering question again, with a wider surveillance platform on one side. VigiLanz reaches across small hospitals, acute care and ambulatory care, ingests near real time data from any record system and fires alerts from rules the hospital configures, with a DoseMeRx dosing model as an add on. MedAware learns what a normal prescription looks like for a patient and flags the ones that do not fit, and hospital investigators at four sites have published on it. A pharmacy running both would still get most of its alert volume from the rules and its novel catches from the outlier model. So the questions differ: rule validation and retirement for one, performance by patient group for the other.
- The detection target is prescriptions that do not fit the patient, caught through outlier detection rather than through a rules library that must anticipate the hazard.
- Hospital investigators at four sites have published on it, two with alerts firing live. At Sheba Medical Center, 89 percent of 315 alerts were judged accurate.
- Integrations are confirmed by named customers rather than asserted, in both health system pharmacy and ambulatory workflows.
- Coverage spans small and critical access hospitals, acute care and a separate ambulatory surveillance product.
- It ingests near real time clinical data regardless of which record system produced it.
- Inovalon publishes its business associate agreement in full, and one set of terms covers every tier.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. MedAware and VigiLanz are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | MedAware | VigiLanz |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | 2012 | 2001 |
| Headquarters | Ra'anana, Israel | Minneapolis, Minnesota, United States |
| Website | medaware.com | inovalon.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
MedAware is an Israeli company whose platform monitors prescribing for medication related risk using machine learning rather than the rule libraries that conventional medication decision support runs on. It was founded in 2012 after a nine year old asthma patient died because his physician selected the wrong drug from an electronic prescribing dropdown, an error no interaction rule was written to catch, because nothing in the prescription broke a rule; the drug was simply wrong for that patient.
Source: AI Health Index, September 2026
VigiLanz is a hospital clinical surveillance platform, founded in Minneapolis in 2001 by David Goldsteen and acquired by Inovalon in February 2024.
Source: AI Health Index, September 2026
Questions buyers ask
How do MedAware and VigiLanz work with the EHR?
At Ballad Health the acute care pharmacy team began operating MedAware natively inside an Epic pharmacy workflow in October 2024, following a partnership announced in July 2023 and confirmed on the health system's own newsroom.
Standards conformance has external checks: VigiLanz is ONC certified for electronic health information export and for antimicrobial use and resistance reporting to the national surveillance network, is a validated NHSN reporting vendor, and publishes its annual real world testing plans and results. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
How are MedAware and VigiLanz priced and sold?
MedAware publishes no price, no unit, no pricing mechanism, no contract shape and no implementation fee guidance. It sells directly to health systems and to physician practices through the athenahealth Marketplace, but nothing says what drives the cost on either route.
For VigiLanz, the ONC certification disclosure on the same page states that the certified product requires a one time implementation fee and an annual licensing fee. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
How do MedAware and VigiLanz handle patient data?
Published material describes what the system does with the data clinically without describing what happens to the data operationally: MedAware publishes no retention period, no de identification practice, no minimum necessary scoping and no statement of whether customer data contributes to model development across institutions.
In VigiLanz's case, the platform ingests near real time admission, medication administration, laboratory, microbiology and medication history data across acute, ambulatory and other settings. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
What evidence is published for MedAware and VigiLanz?
An earlier Harvard Medical School group (JAMIA, 2017) found about 75 percent of alerts valid in a 300 chart sample; that study states it was funded by MedAware, with the company taking no part in chart review or analysis. The opioid use disorder algorithm was validated against two expert opinions on more than 649,000 outpatient records at above 93 percent accuracy.
Inovalon cites VigiLanz as Best in KLAS for pharmacy surveillance eight years running, a market signal about customer satisfaction rather than evidence of clinical benefit. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Inovalon describes VigiLanz as flexible, rule based AI. The engine evaluates configurable rules, and its learned component is the DoseMeRx add on. A rules engine is transparent by construction, which moves the question from model accuracy to rule validation. Inovalon publishes its business associate agreement in full. MedAware states no HIPAA status and publishes no security attestation. VigiLanz names an ONC Health IT certification, which tests software features rather than how Inovalon operates security. Neither publishes results by patient group or a price.